ADMA vs BAC Stock Comparison
ADMA currently leads BAC in this stock comparison, with AIQ scores of 78 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.
What is the main difference between ADMA and BAC?
ADMA leads the current stock comparison as ADMA Biologics, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
ADMA Biologics, Inc. vs Bank of America Corporation
ADMA leads
ADMA leads by 20 AIQ points, primarily on Momentum and Value, and the lead has widened from 7 points over 30 sessions.
Stable: 5 of 6 evidence groups support ADMA, its lead is widening, and its current signal state is conflicted.
ADMA Biologics, Inc.
Bank of America Corporation
The Algovestiq AIQ Score currently favors ADMA over BAC, 78 versus 58 as of Nov 15, 2026. ADMA's advantage is driven primarily by stronger momentum and value, while BAC holds the stronger risk resilience profile. ADMA also shows the stronger technical structure relative to its 50-day moving average. 5 of 6 covered evidence groups favor ADMA today, and the comparison is rated Stable on stability: the leader is throwing conflicting signals. ADMA lead: Strengthening — the AIQ differential moved from 7 to 20 points over 30 sessions.
Compare ADMA Biologics, Inc. and Bank of America Corporation across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare ADMA and BAC against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum91 vs 37ADMA +54
- Risk Resilience56 vs 83BAC +27
- Value80 vs 68ADMA +12
- Quality72 vs 64ADMA +8
5 of 6 evidence groups favor ADMA. ADMA’s edge is concentrated in momentum and value; BAC keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- RSI Overbought — bearish, momentum, short horizon
No factor moved materially.
New signals
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
ADMA's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — ADMA and BAC both carry a full feed there.
The central trade-off
ADMA (ADMA Biologics, Inc.): the stronger current systematic profile, led by momentum and value.
BAC (Bank of America Corporation): the counter-case, on risk resilience.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ADMAADMA on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ADMAADMA on combined revenue and EPS growth.
Value
ADMAADMA on the peer-relative Value factor, by 12 points.
Momentum
ADMAADMA on the Momentum factor, by 54 points.
Lower downside
BACBAC on Risk Resilience, by 27 points.
Analyst upside
ADMAADMA on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | ADMA | BAC | Note |
|---|---|---|---|
| Implied upside to target | +31.6% | +24.1% | ADMA has more room |
| Target dispersion | 0% | +25.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 4 | 25 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
5 of 6 covered evidence groups favor ADMA. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ADMA | 78 vs 58 |
| Fundamentals | ADMA | revenue growth 13.4% vs -3.3%; EPS growth 29.4% vs -23.8%; TTM ROE 11.4% vs 2.3%; gross margin 68.5% vs 60.4%; operating margin 44.9% vs 22.4% |
| Valuation | ADMA | Value 80 vs 68 |
| Technicals | ADMA | Price vs 50-day 29.4% vs -5.6%; vs 200-day 27.6% vs -7% |
| Risk Resilience | BAC | Risk Resilience 56 vs 83 |
| Analyst expectations | ADMA | Target upside 31.6% vs 24.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of ADMA and BAC and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 20 points. (supports the conclusion holding)
- 5 of 6 covered evidence groups point the same way. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ADMA.
How the comparison changed
120 daily snapshots · May 27 – Nov 13ADMA lead: Strengthening — the AIQ differential moved from 7 to 20 points over 30 sessions.
- Today
- ADMA +20
- 78 vs 58
- 7 sessions ago
- ADMA +19
- 77 vs 58
- 30 sessions ago
- ADMA +7
- 69 vs 62
- 90 sessions ago
- BAC +15
- 56 vs 71
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 2 bearish / 2 neutral, conflicted
Only ADMA
- ADX Trend Strengthening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.85%)
- Keltner Channel Breakout — bullish, volatility, short horizon
- RSI Overbought — bearish, momentum, short horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
2 bullish / 2 bearish / 1 neutral, conflicted
Only BAC
- Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
- Downtrend Structure Active — bearish, trend, long horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
Both carry 2 more signals that do not separate them: Death Cross Active, MACD Histogram Expanding Bullish.
ADMA leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +3.32%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BAC closes the Momentum gap — currently 54 points behind, the largest single contributor to ADMA's edge.
- 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ADMA's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ADMA leads on balance| Metric | ADMA | BAC |
|---|---|---|
| Revenue growth (YoY) | 13.4% | -3.3% |
| EPS growth (YoY) | 29.4% | -23.8% |
| Gross margin | 68.5% | 60.4% |
| Operating margin | 44.9% | 22.4% |
| Return on equity (TTM) | 11.4% | 2.3% |
| Debt to equity | 0.46 | 1.28 |
Performance
ADMA leads 4 of 6 windows| Metric | ADMA | BAC |
|---|---|---|
| 1 week (5 sessions) | 7.5% | 3.2% |
| 1 month (20 sessions) | 28.1% | -0.4% |
| 3 months (63 sessions) | 46.5% | -20.1% |
| 6 months (126 sessions) | 65.4% | 2.5% |
| Year to date | -25% | -7.2% |
| 1 year (252 sessions) | -16.9% | -5.7% |
Technicals
ADMA has the stronger structure| Metric | ADMA | BAC |
|---|---|---|
| RSI (14) | 71 | 45.9 |
| ADX (14) | 34 | 27.2 |
| Price vs 50-day | 29.4% | -5.6% |
| Price vs 200-day | 27.6% | -7% |
| Volatility (1M, annualized) | 102.3% | 24.8% |
Risk
BAC is the more resilient| Metric | ADMA | BAC |
|---|---|---|
| Beta | -0.09 | 0.79 |
| Sharpe ratio | -0.01 | -0.22 |
| Sortino ratio | -0.01 | -0.29 |
| Max drawdown | -62.7% | -23.7% |
| Current drawdown | -32.9% | -21.3% |
| Annualized volatility | 58.9% | 22.4% |
| Value at risk (95%) | -4.3% | -2.6% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, ADMA or BAC?
On the Algovestiq AIQ Score, ADMA is the stronger of the two as of Nov 15, 2026, scoring 78 against BAC's 58. The edge comes from momentum and value. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is ADMA or BAC the better buy right now?
ADMA carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 5 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ADMA over BAC?
The composite weights Quality, Value, Momentum and Risk Resilience. ADMA leads Momentum by 54 points; BAC leads Risk Resilience by 27 points; ADMA leads Value by 12 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, ADMA or BAC?
Analyst price targets imply +31.6% upside for ADMA and +24.1% for BAC, so the Street currently favors ADMA. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, ADMA or BAC?
ADMA is the better-valued of the two on the peer-relative Value factor. ADMA on the peer-relative Value factor, by 12 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, ADMA or BAC?
ADMA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, ADMA or BAC?
ADMA on the Momentum factor, by 54 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, ADMA or BAC?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 27 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is ADMA more profitable than BAC?
ADMA leads on the comparable margin measures — gross margin 68.5% vs 60.4%; operating margin 44.9% vs 22.4%; ttm roe 11.4% vs 2.3%.
Is ADMA's lead over BAC getting stronger or weaker?
ADMA lead: Strengthening — the AIQ differential moved from 7 to 20 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the ADMA vs BAC verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 54 points behind, the largest single contributor to ADMA's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; ADMA's conflicting signal state resolves bearish — it currently carries 3 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about ADMA and BAC?
ADMA: 3 bullish / 2 bearish / 2 neutral, conflicted. BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on ADMA is Death Cross Active (bearish, long horizon). On BAC it is Death Cross Active (bearish, long horizon).
Compare ADMA and BAC with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.